175
Participants
Start Date
January 9, 2020
Primary Completion Date
January 1, 2026
Study Completion Date
January 1, 2026
Rifaximin
Rifaximin will be given during weeks 2-4
Glucose and lactulose hydrogen breath testing
Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
RECRUITING
University of Michigan, Ann Arbor
Collaborators (1)
Commonwealth Diagnostics International, Inc.
UNKNOWN
University of Michigan
OTHER